02/06/2025, 01:20 PM UTC
诺维信：仍然过于昂贵Novonesis: Still Too Expensive
1、诺维信与克里斯蒂安·汉森合并成立了诺维信，该公司业务强劲，利润稳定，但增长速度有所下降。2、尽管第三季度业绩稳健，但长期增长放缓，管理层预计未来收入将加速增长，利润率将改善。3、内在价值计算表明，除非实现非常乐观的增长假设，否则该股票不是一笔划算的投资，因此建议谨慎投资。1. Novozymes and Christian Hansen merged to form Novonesis, a company with strong business and stable margins but declining growth rates. 2. Despite Q3/24 results, long-term growth has slowed, and management expects future revenue acceleration and margin improvements. 3. Intrinsic value calculations suggest cautious investment due to the stock not being a bargain unless very optimistic growth assumptions are met.
---
本文由大语言模型（LLM）生成， 旨在为读者提供半导体新闻内容的知识扩展（Beta）。
